ABSTRACT We have demonstrated binding of synthetic bovine parathyroid hormone ] to embryonic avian bone cells in monolayer culture. The binding sites have qualitative and quantitative characteristics of a physiologically important parathyroid hormone (PTH) receptor. At apparent steady state (60 min at 24°C), 5-10% ofelectrolytically labeled, receptorpurified '5I-labeled bPTH-(1-34) bound specifically to the cells whereas nonspecific binding was less than 1% ofthe added labeled hormone. Scatchard analysis showed a single order of PTH binding sites (Kd = 0.6 nM) with approximately 10,000 sites per cell. In this bone cell system, PTH bound to its binding site and stimulated cAMP accumulation over the same concentration range. Bovine PTH-(1-84) bound to the cells with the same apparent affinity as bPTH-(1-34).
Parathyroid hormone (PTH) is believed to exert its effects on mineral homeostasis by influencing the movement of calcium and phosphate into and out of the exchangeable mineral compartment ofbone and by regulating mineral handling and 1,25-dihydroxy vitamin D3 formation by the kidney. The hormone acts on these tissues at least in part by stimulating adenylate cyclase in the target cell membrane to increase intracellular cAMP levels (1) . PTH increases the cAMP content of cultured murine (1) and chicken (2) bone cells, and PTH receptors have been characterized in bovine (3, 4) , avian (5), canine (6) , and human (6) kidney membranes. To date, however, the direct demonstration and quantification of skeletal PTH receptors by radioligand binding assay has not been accomplished.
The present study demonstrates the presence of specific, high-affinity PTH binding sites on cultured embryonic chicken bone cells. Characterization of these binding sites by using electrolyticallylabeled, receptor-purifiedbovine PTH-(1-34) reveals that they display properties consistent with the possibility that they function as hormone receptors coupled to adenylate cyclase. t METHODS We obtained fertilized chicken eggs from Feather Hill Farms (Petaluma, CA) and incubated them in our laboratory. We obtained cell culture supplies from GIBCO, 35-mm tissue culture dishes from Becton Dickinson (Oxnard, CA), collagenase (lot 40C095, 148 units/mg) from Millipore Corporation (Worthington Division, Freehold, NJ), bovine serum albumin (fatty acidfree) from Miles, and Na125I from New England Nuclear. Synthetic human PTH-(1-34) [hPTH-(1-34); synthesized according to the sequence of Brewer et al. (7) ] and human calcitonin were donated by Werner Rittel (Ciba Geigy Company, Basel, Switzerland) and bovine PTH-(1-34) (bPTH; 6000 units/mg) was donated by Beckman. We obtained porcine insulin from Schwarz/Mann (Orangeburg, NY) and glucagon from Sigma.
Bone Cell Isolation and Culture. We used the embryonic chicken bone cell culture method developed by Peck et aL (8) as adapted for chicken bone cell culture by Nijweide et aL (2), butwe did not use chicken embryo extract in the medium. Forty calvaria yielded 12-20 x 106 cells at initial count with a hemocytometer. Cells reached confluence and were used for experiments after 6-7 days of growth.
Binding Studies. Electrolytic labeling and receptor purification ofbPTH-(1-34) were accomplished as described (3) . The specific activities of the preparations of "2I-labeled bPTH- The monolayers were washed four times with 0.9 ml of Hanks' solution at 4°C. Then 0.9 ml of Hanks' solution was added, and the cells were scraped from the dishes with a rubber policeman and transferred to test tubes with a Pasteur pipette. Cell-bound and medium radioactivity were measured in a well-type gamma counter. Dishes containing no cells were incubated and washed in the same manner and the binding values obtained (0.5%) were subtracted from the total binding per culture. Protein was measured by the Lowry method (9), and binding was expressed as the ratio of bound to free hormone per mg of cell protein.
cAMP Measurement. cAMP accumulation was studied under conditions identical to those used in the binding experiments except that the medium also contained 1 mM 3-isobutyl-1-methylxanthine. Control experiments demonstrated that 1 mM 3-isobutyl-1-methylxanthine did not affect 251I-bPTH-(1-34) binding. Cultures were incubated for 5 min. cAMP was extracted from the monolayers with three 1-ml washes of absolute ethanol, and the alcohol was evaporated in a Brinkman sample concentrator. cAMP was measured by the competitive protein binding assay of Gilman (10) and expressed as pmol of cAMP per culture (the ethanol treatment prevented accurate protein measurement). Addition of phosphodiesterase decreased the measured cAMP to undetectable levels, and dilution of extracted cAMP resulted in a dose-displacement curve parallel to that obtained with cAMP standard.
Abbreviations: PTH, parathyroid hormone; hPTH and bPTH, human and bovine PTH.
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Half-maximal cAMP stimulation occurred in the presence of about 3 nM bPTH- (1-34) ; 243 nM bPTH-(1-34) evoked a 10- fold increase in cAMP.
PTH-(1-34) synthesized according to the sequence ofBrewer et aL (7) , found to be less active than bPTH-(1-34) in renal receptor systems (3), was 1/30th as potent in binding and in stimulation of cAMP accumulation (Fig. 3) . bPTH-(1-84) displaced 125I-bPTH-(1-34) as effectively as unlabeled bPTH-(1-34). In these experiments, half-maximal displacement of 125I-bPTH-(1-34) occurred in the presence of 1.0 nM bPTH-(1-34) and 1 (6) , and human (6) renal plasma membranes and in isolated chicken renal tubules (12) showed that the dose range over which unlabeled PTH inhibited-the binding of labeled PTH was similar to that which either stimulated adenylate cyclase (membranes) or stimulated the accumulation of cAMP (tubules). Although it is possible that coincidence plays a role in the consistency of this relationship, we now find that it holds also for a different target of PTH, the bone cell. Because all of the tissues we have examined for PTH receptors and PTH stimulation of adenylate cyclase or cAMP accumulation have been derived from normal animals or humans, we have tentatively concluded that (i) a direct relationship between PTH receptor occupancy and adenylate cyclase activation probably exists under physiologic conditions and (ii) the presence of this relationship in vitro may be an important reflection of a normal state ofcoupling ofthe PTH receptor and adenylate cyclase. The fact that a less-active analog of PTH (6), hPTH-(1-34) synthesized according to the sequence of Brewer et aL (7) , showed similar potency in both the binding and cAMP systems further supports the presence of this relationship of receptor occupancy and cAMP generation in the bone cells.
A body of evidence supports the idea that native PTH-(1-84) must be cleaved to shorter fragments to act on bone tissue (13) . The similarity of the abilities of bPTH-(1-34) and bPTH-(1-84) to displace labeled bPTH-(1-34) is consistent with the interpretation that the two polypeptides bind to chicken bone cells with equal affinity and therefore does not support the idea that the native hormone must be cleaved to act on avian bone. However, cleavage ofbPTH-(1-84) to release active amino-terminal fragments may have occurred during the 1-hr incubation period. We have not yet assessed the degree to which chicken bone cells in monolayer culture metabolize labeled or unlabeled bPTH-(1-34) or bPTH-(1-84).
PTH responsiveness may be altered in various physiologic and pathologic states. Whether such changes involve the PTH-receptor interaction itself or postreceptor modification has not been evaluated. The ability to quantitate skeletal PTH receptors will permit direct study of the initial events in PTH action on bone and may provide answers to such questions.
